Monitoring HCV core antigen during antiviral therapy.

被引：0
|
作者：
Di Bisceglie, AM [1 ]
Strinko, J [1 ]
Osmack, P [1 ]
机构：
[1] St Louis Univ, Hlth Sci Ctr, St Louis, MO 63103 USA
来源：
HEPATOLOGY | 2003年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
560
引用
收藏
页码：430A / 431A
页数：2
相关论文
共 50 条
  • [1] Clinical relevance of serum HCV core antigen level and antiviral therapy response
    Zhang, Y. -Z.
    Wu, W. -J.
    Jin, H.
    Liu, Y. -Y.
    Hu, Y. -W.
    Zhang, Y. -X.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : S68 - S68
  • [2] The diagnostic accuracy of total HCV core antigen in the prediction of primary response to IFN therapy.
    Coco, B
    Oliveri, F
    Moscato, GA
    Colombatto, P
    Ciccorossi, P
    Bonino, F
    Brunetto, MR
    [J]. HEPATOLOGY, 2002, 36 (04) : 289A - 289A
  • [3] High clinical relevance of total HCV core antigen testing for monitoring and predicting response to PEG-IFN/ribavirin combination therapy.
    Maynard, M
    Buti, M
    Esteban, JI
    Tillmann, H
    Wiegand, J
    Manns, M
    Martinot, M
    Marcellin, P
    Berthillon, P
    Pradat, P
    Trepo, C
    [J]. HEPATOLOGY, 2002, 36 (04) : 353A - 353A
  • [4] Tuberculous sepsis during antiviral HCV triple therapy
    Hametner, Stephanie
    Monticelli, Fabio
    Kern, Jan Marco
    Schoefl, Rainer
    Ziachehabi, Alexander
    Maieron, Andreas
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (03) : 637 - 638
  • [5] Antiviral therapy for HCV
    不详
    [J]. LANCET INFECTIOUS DISEASES, 2009, 9 (02): : 86 - 86
  • [6] Impaired cholesterol synthesis in patients infected with HCV-3α.: Effect of antiviral therapy.
    Hofer, H
    Wrba, F
    Steindl-Munda, P
    Mueller, C
    Gangl, A
    Ferenci, P
    [J]. HEPATOLOGY, 2001, 34 (04) : 421A - 421A
  • [7] Among injection drug users, interest is high, but access low to HCV antiviral therapy.
    Seal, KH
    Kral, AH
    Lorvick, J
    Gee, L
    Tsui, JI
    Edlin, BR
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 171 - 171
  • [8] Total HCV core antigen assay:: A new marker of hepatitis C viremia for monitoring the progress of therapy
    Zanetti, AR
    Romanò, L
    Brunetto, M
    Colombo, M
    Bellati, G
    Tackney, C
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2003, 70 (01) : 27 - 30
  • [9] Application of the trak-C™ HCV core assay for monitoring antiviral activity in HCV replication systems
    Cagnon, L
    Wagaman, P
    Bartenschlager, R
    Pietschmann, T
    Gao, TJ
    Kneteman, NM
    Tyrrell, DLJ
    Bahl, C
    Niven, P
    Lee, S
    Simmen, KA
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2004, 118 (01) : 23 - 31
  • [10] Monitoring of HCV infected patients in the early phase of anti-viral therapy using a prototype HCV core antigen ELISA.
    Bahl, C
    Niven, P
    Madjor, D
    Samson, A
    Calcagno, J
    Lee, SR
    [J]. HEPATOLOGY, 2001, 34 (04) : 226A - 226A
12345